VTYX - Ventyx Biosciences, Inc.

14
0.020   0.143%

Share volume: 5,409,090
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$13.98
0.02
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 20%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.21%
1 Month
0.65%
3 Months
75.00%
6 Months
438.46%
1 Year
858.90%
2 Year
55.56%
Key data
Stock price
$14.00
P/E Ratio 
0.00
DAY RANGE
$13.99 - $14.00
EPS 
-$1.56
52 WEEK RANGE
$0.78 - $25.00
52 WEEK CHANGE
$821.05
MARKET CAP 
221.769 M
YIELD 
N/A
SHARES OUTSTANDING 
71.359 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
1.46
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$4,609,304
AVERAGE 30 VOLUME 
$3,488,989
Company detail
CEO: Raju S. Mohan
Region: US
Website: ventyxbio.com
Employees: 30
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Ventyx Biosciences, Inc. develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus.

Recent news